Light therapy treatment
First Claim
1. A method comprising:
- identifying an ischemic event in a patient;
selecting one or more wavelength ranges, from a plurality of wavelength ranges, based on the ability of the wavelength range to inhibit cytochrome c oxidase;
generating light at the one or more selected wavelength ranges, wherein one of the selected wavelength ranges at which the light is generated includes 950 nm; and
applying the light, prior to an onset of reperfusion, to organic tissue that has experienced the ischemic event.
1 Assignment
0 Petitions
Accused Products
Abstract
An exemplary method includes selecting at least one light source configured to generate light at a particular wavelength and applying the light to tissue following an ischemic event. Applying the light to the tissue inhibits cytochrome c oxidase activity. Another exemplary method includes selecting at least one light source configured to generate light at a particular wavelength and applying the light to tissue following an ischemic event and prior to either reoxygenation of the tissue or clinical intervention to reduce cell damage. An exemplary light therapy device includes at least one light source configured to generate light having a wavelength of at least one of approximately 730-770 nm, 850-890 nm, 880-920 nm, and 930-970 nm.
-
Citations
35 Claims
-
1. A method comprising:
-
identifying an ischemic event in a patient; selecting one or more wavelength ranges, from a plurality of wavelength ranges, based on the ability of the wavelength range to inhibit cytochrome c oxidase; generating light at the one or more selected wavelength ranges, wherein one of the selected wavelength ranges at which the light is generated includes 950 nm; and applying the light, prior to an onset of reperfusion, to organic tissue that has experienced the ischemic event. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
-
-
10. A method comprising:
-
identifying organic tissue that has experienced an ischemic event; selecting one or more wavelength ranges based on the ability of the wavelength range to inhibit cytochrome c oxidase; generating light having wavelength ranges of the one or more ranges that are selected from a group of ranges that includes approximately 730-770 nm, approximately 850-890 nm, approximately 880-920 nm, and approximately 930-970 nm; excluding 810 nm from the generated light; and applying the generated light to the organic tissue prior to an onset of reoxygenation of the organic tissue. - View Dependent Claims (11, 12, 13, 14, 15, 16, 17, 18, 19)
-
-
20. A method comprising:
-
identifying a wavelength range based on the ability of the wavelength range to inhibit cytochrome c oxidase, the identified wavelength range from the group of ranges that includes approximately 730-770 nm, approximately 850-890 nm, approximately 880-920 nm, and approximately 930-970 nm, the identified wavelength range not from wavelength ranges that are not included in the group; and applying the light at the identified wavelength range to organic tissue that has experienced an ischemic event, wherein application of the light is at a time prior to an onset of reoxygenation of the tissue and continues after the onset of reoxygenation of the tissue. - View Dependent Claims (21, 22, 23, 24, 25, 26)
-
-
27. A method comprising:
-
selecting two wavelength ranges, each of the two ranges selected based on an ability of the selected wavelength range to inhibit cytochrome c oxidase and each range selected such that, when both of the selected wavelengths are applied to an organic tissue, their combined effect reduces an amount of respiration greater than that of the individual wavelength ranges alone; excluding at least one wavelength based on the ability of the wavelength to activate cytochrome c oxidase; generating light simultaneously at the two selected wavelength ranges and not at the excluded wavelength, wherein the two selected wavelength ranges are selected from the group of wavelength ranges consisting of approximately 730-770 nm, approximately 850-890 nm, approximately 880-920 nm, and approximately 930-970 nm; and applying the generated light to organic tissue that has experienced an ischemic event, wherein application of the light is initiated prior to an reoxygenation of the tissue. - View Dependent Claims (28, 29, 30, 31)
-
-
32. A method comprising:
-
identifying an ischemic event in a patient; selecting one or more wavelength ranges, from a plurality of wavelength ranges, based on the ability of the wavelength range to inhibit cytochrome c oxidase; generating light using light sources at the one or more selected wavelength ranges, wherein one of the selected wavelength ranges at which the light is generated includes 950 nm; applying the light to organic tissue that has experienced the ischemic event; reducing a brightness of the light following an onset of reperfusion; and reducing the brightness by individually disabling the light sources at different times. - View Dependent Claims (33)
-
-
34. A method comprising:
-
identifying an ischemic event in a patient; selecting one or more wavelength ranges, from a plurality of wavelength ranges, based on the ability of the wavelength range to inhibit cytochrome c oxidase; generating light using light sources at the one or more selected wavelength ranges, wherein one of the selected wavelength ranges at which the light is generated includes 950 nm; applying the light to organic tissue that has experienced the ischemic event; reducing a brightness of the light following an onset of reperfusion; and reducing the brightness by disabling discrete groups of the light sources at different times. - View Dependent Claims (35)
-
Specification